Recent News

• 09.02.2025 - PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.25.2025 - PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
• 08.13.2025 - PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
• 07.10.2025 - PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Recent Filings

• 08.29.2025 - S-3 Registration statement under Securities Act of 1933
• 08.25.2025 - 8-K Current report
• 08.25.2025 - 8-K Current report
• 08.25.2025 - EX-99.1 EX-99.1
• 08.25.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 8-K Current report
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - EX-99.1 EX-99.1
• 07.25.2025 - 4 Statement of changes in beneficial ownership of securities